A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza viruson November 12, 2019 at 2:30 am
The mouse is the most widely used animal model for influenza virus research. However, the susceptibility of mice to seasonal influenza virus depends on the strain of mouse and on the strain of the ...
- Influenza Vaccine Market to Reach $6.20 Bn, Globally, by 2026 at 5.9% CAGR: Allied Market Researchon November 12, 2019 at 1:44 am
Influenza Vaccine Market to Reach $6.20 Bn, Globally, by 2026 at 5.9% CAGR: Allied Market Research PR Newswire PORTLAND, Oregon, Nov. 12, 2019 Surge in prevalence of influenza, technological ...
- Now is the time for a flu shot: Steady rise in cases of influenza in Rhine-Siegon November 11, 2019 at 11:09 pm
Rhine-Sieg District With an ever increasing number of cases of influenza, doctors recommend that people get flu shots - and in November at the latest. In Rhine-Sieg last year there were 1,460 cases of ...
- Seasonal Influenza Vaccine Market Analysis, Driving Forces, and Product Developmenton November 11, 2019 at 8:26 pm
Nov 12, 2019 (AmericaNewsHour) -- Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, ...
- Influenza Medication Market Huge Market Growth Till 2024 | By Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Roche, GSK, Novartison November 11, 2019 at 12:41 pm
Nov 11, 2019 (Reporthive Research via COMTEX) -- Chicago, United States, Nov 11, 2019 --The global Influenza Medication Market 2019 research provides a basic overview of the industry including ...
- One Council Bluffs school already deep cleaned for influenza germson November 8, 2019 at 12:09 pm
BANDUR VISITED ONE SCHOOL THAT’S TRYING TO KEEP THE HEALTHY KIDS IN CLASS. MICHELLE: THE FLU AND STREP THROAT ARE DISRUPTING CLASSES AT COLLEGE VIEW ELEMENTARY SCHOOL IN COUNCIL BLUFFS. IT’S SEEN A ...
- Changes of urine metabolite profiles are induced by inactivated influenza vaccine inoculations in miceon November 7, 2019 at 2:14 am
In this study, mouse urine metabolomics analysis with 1 H NMR was performed using different influenza vaccines of varying toxicity to assess the usefulness of 1 H NMR in evaluating vaccine toxicity.
- Ministry of Health and Prevention organizes awareness workshop on the importance of the seasonal influenza vaccineon November 5, 2019 at 9:12 pm
The Ministry of Health and Prevention, MoHAP, yesterday (Monday), organized a workshop on the importance of the seasonal influenza vaccine, to raise awareness of the community and health workers at ...
- FDA approves Sanofi influenza vaccine for adults 65 and olderon November 5, 2019 at 4:46 am
The U.S. Food and Drug Administration approved a supplemental Biologics License Application for the influenza vaccine Fluzone High-Dose Quadrivalent from Bridgewater-based Sanofi, for use in adults 65 ...
- Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and olderon November 4, 2019 at 4:29 pm
FDA approves Fluzone ® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older *Will be available in fall 2020, in time for the 2020-2021 flu season PARIS - November 4, 2019 – ...
via Bing News